Physician

Paul M Armistead, M.D., PHD

According to 2025 Medicare claims, Paul Armistead, M.D., PHD (NPI: 1235221524) practices hematopoietic cell transplantation and cellular therapy in the Raleigh-Cary, NC market, with the plurality of this provider's patient population coming from Wake, NC. This provider's primary affiliated billing organization is UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (NPI: 1780669200; TIN: 561732213) and primary practice location at 27514-4220.

Armistead's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 51 traditional Medicare patients, billed 296 HCPCS/CPT codes, and received $20,086 in Medicare payments. The top billing code was 99215 (Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more). Part D data shows 489 prescription claims across 33 beneficiaries totaling $1,331,093 in drug costs, led by Jakafi (Ruxolitinib Phosphate). Open Payments data shows 14 records totaling $8,701. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved up and down with repeated peaks and valleys, starting at $19,313 and ending at $20,086. Concurrently, Part D prescription costs have risen steadily, from $96,513 to $1,331,093. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	59	245	$19,313
2016	41	226	$14,740
2017	41	215	$16,814
2018	47	215	$17,472
2019	45	194	$16,167
2020	57	314	$26,534
2021	59	370	$31,719
2022	58	286	$24,277
2023	61	200	$18,640
2024	51	296	$20,086

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	14	186	$96,513
2016	11	105	$96,306
2017	N/R	127	$127,363
2018	12	257	$238,025
2019	16	268	$340,034
2020	25	275	$234,269
2021	33	489	$296,092
2022	36	474	$658,051
2023	35	556	$1,138,111
2024	33	489	$1,331,093

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

No connected DME records

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	30	59	$99
99233	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes	18	111	$85
G2212	Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or	15	38	$23
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	28	51	$12

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Jakafi	Ruxolitinib Phosphate	41	1,230	$673,227
Rezurock	Belumosudil Mesylate	30	900	$634,196
Valacyclovir	Valacyclovir Hcl	59	2,250	$2,233
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	14	420	$1,588
Prednisone	Prednisone	28	1,969	$392

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	14	$8,701	Kite Pharma, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Paul M. Armistead, M.D., PHD?

Tedicare shows public-source Medicare data for Paul M. Armistead, M.D., PHD (NPI 1235221524), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Paul M. Armistead, M.D., PHD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Paul M. Armistead, M.D., PHD?

Paul M. Armistead, M.D., PHD is linked to UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (billing NPI 1780669200) in the available physician profile data.

Does Paul M. Armistead, M.D., PHD have Open Payments data?

Paul M. Armistead, M.D., PHD has 14 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.